Literature DB >> 33687669

Pluripotent Stem Cells for Cell Therapy.

Insa S Schroeder1.   

Abstract

In an increasingly geriatric population, in which elderly people frequently face chronic diseases and degenerative conditions, cell therapies as part of novel regenerative medicine approaches are of great interest. Even though today's cell therapies mostly rely on adult stem cells like the mesenchymal stem cells or primary somatic cells, pluripotent stem cells represent an enormously versatile cell model to explore possible new avenues in the field of regenerative medicine due to their capacity to grow indefinitely and to differentiate into the desired cell types. The discovery of reprogramming somatic cells into induced pluripotent stem cells augmented the pool of applicable cell entities so that researchers nowadays can resort to embryonic stem cells, but also to a plethora of patient- and disease-specific induced pluripotent stem cells. The ease of targeted genome engineering is an additional benefit that allows using pluripotent stem cells for disease modeling, drug discovery, and the development of cell therapies. However, the task is still demanding as the generation of subpopulations and a sufficient cell maturation for some cell entities have yet to be achieved. Likewise, even though for some applications the cells of interest can be produced in the large-scale dimensions and purity that are required for clinical purposes, proper integration, and function in the host tissue remain challenging. Nonetheless, the immense progress that has been made over the last decades warrants the prominent role of pluripotent stem cells in regenerative medicine as in vitro models to broaden our knowledge of disease onset/progression and treatment as well as in vivo as a substitution of damaged/aged tissue.

Entities:  

Keywords:  Cell therapy; Clinical translation; Differentiation; Embryonic stem cells; Induced pluripotent stem cells

Mesh:

Year:  2021        PMID: 33687669     DOI: 10.1007/978-1-0716-1225-5_2

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  38 in total

1.  Human Pluripotent Stem Cell-Derived Atrial and Ventricular Cardiomyocytes Develop from Distinct Mesoderm Populations.

Authors:  Jee Hoon Lee; Stephanie I Protze; Zachary Laksman; Peter H Backx; Gordon M Keller
Journal:  Cell Stem Cell       Date:  2017-08-03       Impact factor: 24.633

2.  Canonical Wnt signaling promotes pacemaker cell specification of cardiac mesodermal cells derived from mouse and human embryonic stem cells.

Authors:  Wenbin Liang; Pengcheng Han; Elizabeth H Kim; Jordan Mak; Rui Zhang; Angelo G Torrente; Joshua I Goldhaber; Eduardo Marbán; Hee Cheol Cho
Journal:  Stem Cells       Date:  2019-12-30       Impact factor: 6.277

3.  A Human iPSC Double-Reporter System Enables Purification of Cardiac Lineage Subpopulations with Distinct Function and Drug Response Profiles.

Authors:  Joe Z Zhang; Vittavat Termglinchan; Ning-Yi Shao; Ilanit Itzhaki; Chun Liu; Ning Ma; Lei Tian; Vicky Y Wang; Alex C Y Chang; Hongchao Guo; Tomoya Kitani; Haodi Wu; Chi Keung Lam; Kazuki Kodo; Nazish Sayed; Helen M Blau; Joseph C Wu
Journal:  Cell Stem Cell       Date:  2019-03-14       Impact factor: 24.633

4.  Robust derivation of epicardium and its differentiated smooth muscle cell progeny from human pluripotent stem cells.

Authors:  Dharini Iyer; Laure Gambardella; William G Bernard; Felipe Serrano; Victoria L Mascetti; Roger A Pedersen; Sanjay Sinha; Amarnath Talasila
Journal:  Development       Date:  2016-03-01       Impact factor: 6.868

5.  Expansion and patterning of cardiovascular progenitors derived from human pluripotent stem cells.

Authors:  Matthew J Birket; Marcelo C Ribeiro; Arie O Verkerk; Dorien Ward; Ana Rita Leitoguinho; Sabine C den Hartogh; Valeria V Orlova; Harsha D Devalla; Verena Schwach; Milena Bellin; Robert Passier; Christine L Mummery
Journal:  Nat Biotechnol       Date:  2015-07-20       Impact factor: 54.908

6.  Atrial-like cardiomyocytes from human pluripotent stem cells are a robust preclinical model for assessing atrial-selective pharmacology.

Authors:  Harsha D Devalla; Verena Schwach; John W Ford; James T Milnes; Said El-Haou; Claire Jackson; Konstantinos Gkatzis; David A Elliott; Susana M Chuva de Sousa Lopes; Christine L Mummery; Arie O Verkerk; Robert Passier
Journal:  EMBO Mol Med       Date:  2015-04       Impact factor: 12.137

7.  Modeling Atrial Fibrillation using Human Embryonic Stem Cell-Derived Atrial Tissue.

Authors:  Zachary Laksman; Marianne Wauchop; Eric Lin; Stephanie Protze; Jeehoon Lee; Wallace Yang; Farzad Izaddoustdar; Sanam Shafaattalab; Lior Gepstein; Glen F Tibbits; Gordon Keller; Peter H Backx
Journal:  Sci Rep       Date:  2017-07-13       Impact factor: 4.379

8.  Subtype-specific differentiation of cardiac pacemaker cell clusters from human induced pluripotent stem cells.

Authors:  Patrick A Schweizer; Fabrice F Darche; Nina D Ullrich; Pascal Geschwill; Boris Greber; Rasmus Rivinius; Claudia Seyler; Karin Müller-Decker; Andreas Draguhn; Jochen Utikal; Michael Koenen; Hugo A Katus; Dierk Thomas
Journal:  Stem Cell Res Ther       Date:  2017-10-16       Impact factor: 6.832

9.  Atrial-like Engineered Heart Tissue: An In Vitro Model of the Human Atrium.

Authors:  Marta Lemme; Bärbel M Ulmer; Marc D Lemoine; Antonia T L Zech; Frederik Flenner; Ursula Ravens; Hermann Reichenspurner; Miriam Rol-Garcia; Godfrey Smith; Arne Hansen; Torsten Christ; Thomas Eschenhagen
Journal:  Stem Cell Reports       Date:  2018-11-08       Impact factor: 7.765

10.  BNC1 regulates cell heterogeneity in human pluripotent stem cell-derived epicardium.

Authors:  Laure Gambardella; Sophie A McManus; Victoria Moignard; Derya Sebukhan; Agathe Delaune; Simon Andrews; William G Bernard; Maura A Morrison; Paul R Riley; Berthold Göttgens; Nicolas Gambardella Le Novère; Sanjay Sinha
Journal:  Development       Date:  2019-12-13       Impact factor: 6.868

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.